JP2018510207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510207A5 JP2018510207A5 JP2017560843A JP2017560843A JP2018510207A5 JP 2018510207 A5 JP2018510207 A5 JP 2018510207A5 JP 2017560843 A JP2017560843 A JP 2017560843A JP 2017560843 A JP2017560843 A JP 2017560843A JP 2018510207 A5 JP2018510207 A5 JP 2018510207A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- condition
- compound according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 90
- 150000001875 compounds Chemical class 0.000 claims 54
- 201000010099 disease Diseases 0.000 claims 48
- 208000035475 disorder Diseases 0.000 claims 42
- 230000002265 prevention Effects 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 23
- 239000012453 solvate Substances 0.000 claims 23
- -1 perhaloalkyl Chemical group 0.000 claims 22
- 229940002612 prodrug Drugs 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 208000011580 syndromic disease Diseases 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 9
- 206010061218 Inflammation Diseases 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 208000027866 inflammatory disease Diseases 0.000 claims 8
- 230000004054 inflammatory process Effects 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- 208000017520 skin disease Diseases 0.000 claims 6
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 4
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 4
- 208000035690 Familial cold urticaria Diseases 0.000 claims 4
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims 4
- 206010072219 Mevalonic aciduria Diseases 0.000 claims 4
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 4
- 206010031252 Osteomyelitis Diseases 0.000 claims 4
- 210000000068 Th17 cell Anatomy 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 230000008938 immune dysregulation Effects 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 230000000737 periodic effect Effects 0.000 claims 4
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 208000012414 A20 haploinsufficiency Diseases 0.000 claims 2
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 2
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000022210 Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 201000009182 Chikungunya Diseases 0.000 claims 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010061788 Corneal infection Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 108700036803 Deficiency of interleukin-1 receptor antagonist Proteins 0.000 claims 2
- 208000001490 Dengue Diseases 0.000 claims 2
- 206010012310 Dengue fever Diseases 0.000 claims 2
- 241000710829 Dengue virus group Species 0.000 claims 2
- 206010012559 Developmental delay Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 241001475178 Dira Species 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000006968 Helminthiasis Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020633 Hyperglobulinaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000006311 Pyoderma Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 208000010265 Sweet syndrome Diseases 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 241000907316 Zika virus Species 0.000 claims 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 208000007474 aortic aneurysm Diseases 0.000 claims 2
- 206010003441 asbestosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000025255 bacterial arthritis Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 2
- 150000004697 chelate complex Chemical class 0.000 claims 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 208000024858 congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 208000025729 dengue disease Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000000750 endocrine system Anatomy 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 201000005033 granulomatous angiitis Diseases 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 208000004593 pneumococcal meningitis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000005956 sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay Diseases 0.000 claims 2
- 230000037432 silent mutation Effects 0.000 claims 2
- 230000000392 somatic effect Effects 0.000 claims 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 150000003852 triazoles Chemical class 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 0 *c(c1c2***1)c(***1)c1c2NC(NSC1**B[*+]1)=O Chemical compound *c(c1c2***1)c(***1)c1c2NC(NSC1**B[*+]1)=O 0.000 description 3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131251A JP7566699B2 (ja) | 2015-02-16 | 2021-08-11 | スルホニル尿素及び関連化合物並びにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015900507 | 2015-02-16 | ||
| AU2015900507A AU2015900507A0 (en) | 2015-02-16 | Sulfonylureas and related compounds and use of same | |
| PCT/AU2016/050103 WO2016131098A1 (en) | 2015-02-16 | 2016-02-16 | Sulfonylureas and related compounds and use of same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131251A Division JP7566699B2 (ja) | 2015-02-16 | 2021-08-11 | スルホニル尿素及び関連化合物並びにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510207A JP2018510207A (ja) | 2018-04-12 |
| JP2018510207A5 true JP2018510207A5 (enExample) | 2019-03-28 |
| JP6929792B2 JP6929792B2 (ja) | 2021-09-01 |
Family
ID=56691944
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560843A Active JP6929792B2 (ja) | 2015-02-16 | 2016-02-16 | スルホニル尿素及び関連化合物並びにその使用 |
| JP2021131251A Active JP7566699B2 (ja) | 2015-02-16 | 2021-08-11 | スルホニル尿素及び関連化合物並びにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131251A Active JP7566699B2 (ja) | 2015-02-16 | 2021-08-11 | スルホニル尿素及び関連化合物並びにその使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10538487B2 (enExample) |
| EP (3) | EP3259253B1 (enExample) |
| JP (2) | JP6929792B2 (enExample) |
| KR (2) | KR102948713B1 (enExample) |
| CN (3) | CN113582889B (enExample) |
| AU (3) | AU2016222278B2 (enExample) |
| CA (2) | CA3250390A1 (enExample) |
| CL (2) | CL2017002097A1 (enExample) |
| CY (1) | CY1122832T1 (enExample) |
| DK (2) | DK3259253T3 (enExample) |
| ES (2) | ES2777626T3 (enExample) |
| HR (2) | HRP20200214T1 (enExample) |
| HU (1) | HUE055755T2 (enExample) |
| IL (2) | IL253661B2 (enExample) |
| LT (2) | LT3578547T (enExample) |
| MA (3) | MA41553B1 (enExample) |
| MD (1) | MD3259253T2 (enExample) |
| ME (1) | ME03737B (enExample) |
| MX (2) | MX2017010528A (enExample) |
| MY (2) | MY193765A (enExample) |
| NZ (1) | NZ733948A (enExample) |
| PE (2) | PE20221627A1 (enExample) |
| PL (2) | PL3578547T3 (enExample) |
| PT (2) | PT3578547T (enExample) |
| RS (2) | RS62164B1 (enExample) |
| RU (1) | RU2739356C2 (enExample) |
| SG (2) | SG10202002599XA (enExample) |
| SI (2) | SI3259253T1 (enExample) |
| SM (1) | SMT202000192T1 (enExample) |
| WO (1) | WO2016131098A1 (enExample) |
Families Citing this family (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| BR112018016671A2 (pt) * | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| MA44729A (fr) * | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| WO2018103583A1 (en) * | 2016-12-05 | 2018-06-14 | Zibo Anxuan Pharmaceutical Science And Technology Co., Ltd. | N-hydroxy-benzene-sulfonamide derivatives and their uses thereof |
| UA126675C2 (uk) * | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| GB2561540A (en) * | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| ES3002968T3 (en) * | 2017-07-14 | 2025-03-10 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| US11370763B2 (en) | 2017-07-24 | 2022-06-28 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| JP7412328B2 (ja) * | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| DE102017118230B4 (de) * | 2017-08-10 | 2021-04-22 | Christoph Lucks | Verfahren zur Analyse und/oder Überwachung von Brücken sowie entsprechendes System und entsprechende Verwendung |
| EP3668862A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019034693A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| TW201910317A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| AU2018317800A1 (en) * | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019034697A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| TW201910314A (zh) * | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| WO2019092171A1 (en) * | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019092172A1 (en) * | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) * | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| US12168653B2 (en) | 2018-03-02 | 2024-12-17 | Inflazome Limited | Sulfonamide derivates as NLRP3 inhibitors |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| US20200399242A1 (en) * | 2018-03-02 | 2020-12-24 | Inflazome Limited | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| WO2019166619A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| JP7229565B2 (ja) | 2018-03-21 | 2023-02-28 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | メラノーマを治療するための方法 |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| IL278125B (en) * | 2018-04-23 | 2022-09-01 | Corcept Therapeutics Inc | Methods for the preparation of regioselective n-alkyl triazoles |
| CR20200588A (es) | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Compuestos novedosos |
| CN108404117B (zh) * | 2018-05-29 | 2020-06-30 | 广东龙帆生物科技有限公司 | 核苷酸结合寡聚化结构域样受体蛋白在治疗寨卡病毒感染药物中的应用 |
| JP2021529187A (ja) | 2018-07-03 | 2021-10-28 | ノバルティス アーゲー | Ｎｌｒｐモジュレータ |
| US20210395241A1 (en) * | 2018-07-03 | 2021-12-23 | Novartis Ag | Nlrp modulators |
| JP2021529780A (ja) * | 2018-07-03 | 2021-11-04 | ノバルティス アーゲー | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| MX2021000660A (es) * | 2018-07-20 | 2021-03-25 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1. |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| SG11202101480XA (en) | 2018-08-15 | 2021-03-30 | Inflazome Ltd | Novel sulfonamideurea compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| CN113015730A (zh) * | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CN113166081A (zh) * | 2018-11-13 | 2021-07-23 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CR20210235A (es) | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| EP3880658A1 (en) * | 2018-11-16 | 2021-09-22 | Novartis AG | The compounds and compositions for treating conditions associated with nlrp activity |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| AU2020210117B2 (en) | 2019-01-14 | 2025-03-13 | Zydus Lifesciences Limited | Novel substituted sulfonylurea derivatives |
| US20220227707A1 (en) * | 2019-01-22 | 2022-07-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| CN113660983A (zh) * | 2019-01-25 | 2021-11-16 | 诺瑟拉有限公司 | 氨基甲酸酯衍生物及其用途 |
| CN113614063A (zh) | 2019-02-22 | 2021-11-05 | Pi工业有限公司 | 合成氨茴二酰胺化合物及其中间体的方法 |
| EP3934636A1 (en) * | 2019-03-06 | 2022-01-12 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Inhibitors of ngal protein |
| GB201905265D0 (en) * | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| CN111848461A (zh) * | 2019-04-29 | 2020-10-30 | 苏州大学 | Nlrp3炎症小体抑制剂及其制备方法和应用 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| WO2020249669A1 (en) * | 2019-06-12 | 2020-12-17 | NodThera Limited | Sulfonamide derivatives and uses thereof |
| HUE067378T2 (hu) | 2019-06-12 | 2024-10-28 | Nodthera Ltd | Szulfonilurea származékok és alkalmazásaik |
| JP7661248B2 (ja) | 2019-06-12 | 2025-04-14 | ノッドセラ リミテッド | スルホニル尿素誘導体及びその使用 |
| CN114008030A (zh) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| WO2021009567A1 (en) * | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| AU2020312800B2 (en) * | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| JP2022545400A (ja) * | 2019-08-16 | 2022-10-27 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体 |
| JP2022547882A (ja) * | 2019-09-06 | 2022-11-16 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤 |
| CN114746087A (zh) * | 2019-09-12 | 2022-07-12 | 载度思生命科学有限公司 | 新的经取代的亚砜亚胺衍生物 |
| WO2021089781A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
| EP4054563A1 (en) * | 2019-11-07 | 2022-09-14 | Inflazome Limited | Treatment and prevention of neuroinflammation or an inflammatory brain disorder |
| JP2023501319A (ja) * | 2019-11-07 | 2023-01-18 | インフレイゾーム リミテッド | 神経変性疾患の処置および予防 |
| JP2023501334A (ja) * | 2019-11-07 | 2023-01-18 | インフレイゾーム リミテッド | 自己炎症性疾患の処置 |
| WO2021089776A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment and prevention of a traumatic brain disorder |
| GB201916237D0 (en) * | 2019-11-07 | 2019-12-25 | Inflazome Ltd | Novel treatment |
| CA3158123A1 (en) * | 2019-11-12 | 2021-05-20 | Yonggang Wei | Amide derivative and preparation method therefore and use thereof in medicine |
| WO2021111351A1 (en) * | 2019-12-03 | 2021-06-10 | Cadila Healthcare Limited | Novel substituted sulfonylurea and sulfoximineurea derivatives |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US20230121952A1 (en) | 2020-02-18 | 2023-04-20 | Inflazome Limited | Compounds |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CN111358778A (zh) * | 2020-03-17 | 2020-07-03 | 中国医科大学附属第一医院 | Mcc950在制备预防或治疗阿尔茨海默病的药物中的应用 |
| US20230146308A1 (en) | 2020-03-19 | 2023-05-11 | Softhale Nv | Method for the treatment nlrp3-associated diseases |
| WO2021219784A1 (en) * | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| CN115768749B (zh) * | 2020-06-11 | 2024-04-19 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物 |
| US12624010B2 (en) | 2020-06-19 | 2026-05-12 | Ac Immune Sa | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway |
| WO2022022646A1 (zh) * | 2020-07-29 | 2022-02-03 | 南京明德新药研发有限公司 | 含硒五元杂芳环化合物 |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| JP7865948B2 (ja) * | 2020-09-04 | 2026-05-26 | ノッドセラ リミテッド | アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用 |
| US20250073218A1 (en) * | 2020-11-04 | 2025-03-06 | Uppthera | Nlrp3 protein degradation inducing compound |
| FR3115682B1 (fr) * | 2020-11-05 | 2023-02-24 | Roquette Freres | Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique |
| US20230416751A1 (en) * | 2020-11-13 | 2023-12-28 | University Of Miami | Materials and methods for treating corneal dysfunction |
| AU2021381396A1 (en) * | 2020-11-20 | 2023-06-22 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| US20240018166A1 (en) * | 2020-11-25 | 2024-01-18 | VenatoRx Pharmaceuticals, Inc. | Sulfonyl urea nlrp3 inflammasome inhibitors |
| KR102802013B1 (ko) * | 2021-02-03 | 2025-05-07 | 환인제약 주식회사 | 알츠하이머병 치료를 위한 nlrp3 인플라마좀 소분자 억제제 |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| EP4330236A4 (en) * | 2021-04-30 | 2025-09-24 | Denali Therapeutics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| IT202100011237A1 (it) | 2021-05-03 | 2022-11-03 | Univ Degli Studi Di Torino | Composti inibitori dell’inflammasoma nlrp3 e loro uso |
| CN116635374B (zh) * | 2021-05-10 | 2025-05-06 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| CN116917282B (zh) * | 2021-05-10 | 2026-08-11 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| TW202246230A (zh) * | 2021-05-10 | 2022-12-01 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| WO2022269010A1 (en) | 2021-06-23 | 2022-12-29 | F. Hoffmann-La Roche Ag | A crystalline potassium salt of 1-ethyl- n -((1,2,3,5,6,7-hexahydro- s -indacen-4-yl)carbamoyl)piperidine-4 -sulfonamide |
| WO2023288039A1 (en) * | 2021-07-16 | 2023-01-19 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| ES2948511A1 (es) * | 2021-09-08 | 2023-09-13 | Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa | Derivados de n-sulfonilureas y su uso terapeutico |
| CN115894478B (zh) * | 2021-09-30 | 2025-04-04 | 杭州民生药物研究院有限公司 | 一种新型吡啶并吡唑类杂环化合物及其应用 |
| KR20230066899A (ko) | 2021-11-08 | 2023-05-16 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2023098612A1 (zh) * | 2021-12-03 | 2023-06-08 | 南京明德新药研发有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| JP2025502732A (ja) | 2021-12-22 | 2025-01-28 | エーシー・イミューン・エス・アー | ジヒドロオキサゾール誘導体化合物 |
| WO2023230002A1 (en) * | 2022-05-23 | 2023-11-30 | VenatoRx Pharmaceuticals, Inc. | Nlrp3 inflammasome inhibitors |
| US20250388568A1 (en) * | 2022-07-06 | 2025-12-25 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| JP2025524640A (ja) | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| WO2024023266A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| KR20240022938A (ko) | 2022-08-12 | 2024-02-20 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| AR130318A1 (es) * | 2022-08-29 | 2024-11-27 | Japan Tobacco Inc | Compuestos de pirazolopirimidina y su uso médico |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN115772173B (zh) * | 2022-12-20 | 2024-04-16 | 武汉国粹医药科技有限公司 | 苯并呋喃类化合物、其制备方法及其应用和抗菌剂 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025046419A1 (ko) | 2023-08-25 | 2025-03-06 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| TW202513060A (zh) * | 2023-09-29 | 2025-04-01 | 瑞士商諾華公司 | 用於降低心血管疾病的風險之nlrp3抑制劑 |
| KR20260105779A (ko) * | 2023-12-01 | 2026-07-07 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 설포닐유레아 유도체 및 이의 응용 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| CN122555707A (zh) | 2024-01-17 | 2026-08-11 | Ac免疫有限公司 | 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物 |
| CN122555708A (zh) | 2024-01-17 | 2026-08-11 | Ac免疫有限公司 | 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物 |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| CN120463630A (zh) * | 2024-02-09 | 2025-08-12 | 杭州矩阵生物药业有限公司 | 具有nlrp3抑制活性的磺酰脲类衍生物及其应用 |
| CN118063333A (zh) * | 2024-02-29 | 2024-05-24 | 浙江鼎龙科技股份有限公司 | 一种2-羟基-4-乙基苯胺及其盐酸盐的制备方法 |
| CN118638081B (zh) * | 2024-05-23 | 2026-05-08 | 武汉科技大学 | 磺酰脲类化合物 |
| WO2026001614A1 (zh) * | 2024-06-26 | 2026-01-02 | 拜西欧斯（北京）生物技术有限公司 | 一种磺酰脲类化合物及其用途 |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026132518A1 (en) | 2024-12-20 | 2026-06-25 | Ac Immune Sa | Heterocyclic compounds modulating the nlrp3 inflammasome pathway |
| CN120535399B (zh) * | 2025-06-11 | 2026-03-24 | 上海麦克林生化科技股份有限公司 | 4-(2,2,2-三氟-1-烷氧基乙基)苯酚的制备方法 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB797474A (en) | 1955-07-20 | 1958-07-02 | Boehringer & Soehne Gmbh | Sulphonylurea derivatives |
| US3242174A (en) | 1962-02-06 | 1966-03-22 | Pfizer & Co C | 1-(tertiary aminosulfonyl)-3-(hydrocarbon) ureas |
| US3305556A (en) | 1962-11-23 | 1967-02-21 | Pfizer & Co C | Novel hypoglycemic agents |
| NL129208C (enExample) | 1965-07-14 | |||
| CH509992A (de) | 1966-08-08 | 1971-07-15 | Hoffmann La Roche | Verfahren zur Herstellung von Sulfonamiden |
| NL131473C (enExample) | 1966-10-28 | |||
| BE754588A (fr) | 1969-08-07 | 1971-02-08 | Hoechst Ag | Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances |
| FR2063472A5 (enExample) | 1969-10-17 | 1971-07-09 | Mercier Pierre | |
| GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| AU571869B2 (en) | 1983-05-09 | 1988-04-28 | E.I. Du Pont De Nemours And Company | Pyridyl- and pyrimidyl- sulphonamides |
| DE3479213D1 (en) | 1983-05-16 | 1989-09-07 | Ciba Geigy Ag | Herbicidally active and plant growth regulating pyrimidine derivatives, their preparation and use |
| JPS6045573A (ja) | 1983-08-22 | 1985-03-12 | Nissan Chem Ind Ltd | ピラゾ−ルスルホニルウレア誘導体，その製法および該誘導体を含有する選択性除草剤 |
| US4723991A (en) | 1984-03-23 | 1988-02-09 | E. I. Du Pont De Nemours And Company | Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity |
| US4659369A (en) | 1984-08-27 | 1987-04-21 | E. I. Du Pont De Nemours And Company | Herbicidal acetals and ketals |
| AU578307B2 (en) | 1984-09-17 | 1988-10-20 | E.I. Du Pont De Nemours And Company | Herbicidal pyrazolesulfonamides |
| FI855180L (fi) | 1985-01-18 | 1986-07-19 | Nissan Chemical Ind Ltd | Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift. |
| JPH0720957B2 (ja) | 1985-11-26 | 1995-03-08 | 日産化学工業株式会社 | ピラゾ−ルスルホニルウレア誘導体、製法および除草剤 |
| JP2570686B2 (ja) | 1985-12-23 | 1997-01-08 | 日産化学工業株式会社 | ピラゾ−ル誘導体 |
| US4830660A (en) | 1986-06-19 | 1989-05-16 | Nissan Chemical Industries, Ltd. | Imidazolesulfonamide derivatives and herbicides |
| ES2037738T3 (es) | 1986-09-26 | 1993-07-01 | Ciba-Geigy Ag | Procedimiento para la obtencion de aminopirazinonas y aminotriazinonas. |
| US4802908A (en) | 1987-01-22 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2-(1H)-pyrazinones |
| AU7165591A (en) | 1990-01-22 | 1991-08-05 | E.I. Du Pont De Nemours And Company | Herbicidal sulfonylureas |
| ZA915371B (en) | 1990-07-17 | 1993-03-31 | Lilly Co Eli | Antitumor compositions and methods of treatment |
| US5472933A (en) | 1990-08-29 | 1995-12-05 | E. I. Du Pont De Nemours And Company | Herbicidal pyrrolesulfonylureas |
| US5214206A (en) | 1990-11-07 | 1993-05-25 | Warner-Lambert Company | Aminosulfonyl urea acat inhibitors |
| DE4039733A1 (de) | 1990-12-13 | 1992-06-17 | Basf Ag | Substituierte 5-aminopyrazole |
| CZ36394A3 (en) | 1991-08-19 | 1994-07-13 | Du Pont | Substituted imidazilonone derivatives and pharmaceutical preparations based thereon |
| CZ36294A3 (en) | 1991-08-19 | 1994-07-13 | Du Pont | Substituted imidazilonone derivatives and pharmaceutical preparations based thereon |
| US5169860A (en) * | 1992-03-13 | 1992-12-08 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| US5219856A (en) | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
| JPH0645573A (ja) | 1992-07-23 | 1994-02-18 | Nikon Corp | 赤外線固体撮像装置 |
| JPH06199053A (ja) | 1992-12-28 | 1994-07-19 | Sankyo Kagaku Kk | 感熱転写記録用色素 |
| JPH06199054A (ja) | 1992-12-28 | 1994-07-19 | Dainippon Printing Co Ltd | 熱転写シート |
| JPH06199047A (ja) | 1993-01-08 | 1994-07-19 | New Oji Paper Co Ltd | 感熱記録体 |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| AU7007696A (en) | 1995-09-22 | 1997-04-09 | E.I. Du Pont De Nemours And Company | Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines |
| JP3992291B2 (ja) | 1995-09-28 | 2007-10-17 | アスビオファーマ株式会社 | キナゾリン誘導体 |
| AU1735497A (en) | 1996-02-26 | 1997-09-10 | Sumitomo Pharmaceuticals Company, Limited | Sulfonylureidopyrazole derivatives |
| DK1270565T3 (da) * | 1997-01-29 | 2004-10-04 | Pfizer | 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater |
| US6022984A (en) | 1998-07-27 | 2000-02-08 | Pfizer Inc. | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors |
| JP2000053649A (ja) | 1998-08-11 | 2000-02-22 | Sumitomo Pharmaceut Co Ltd | スルホニルウレイドピラゾール誘導体 |
| EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
| EA200100972A1 (ru) | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| BR0014003A (pt) * | 1999-09-14 | 2002-05-21 | Pfizer Prod Inc | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra |
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| WO2001057037A1 (en) | 2000-02-04 | 2001-08-09 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| AR039352A1 (es) | 2001-05-18 | 2005-02-16 | Solvay Pharm Gmbh | Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5. |
| AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| FI110677B (fi) | 2001-10-12 | 2003-03-14 | Jujo Thermal Oy | Lämpöherkkä tallennusmateriaali |
| CA2463975A1 (en) | 2001-10-26 | 2003-05-01 | Maria Emilia Di Francesco | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| AU2002341321A1 (en) | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| UA80131C2 (en) | 2002-05-28 | 2007-08-27 | Dimensional Pharm Inc | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| KR20060113699A (ko) | 2003-10-03 | 2006-11-02 | 포톨라 파마슈티컬스, 인코포레이티드 | 치환된 이소퀴놀리논 |
| PL1668002T3 (pl) | 2003-10-03 | 2010-02-26 | Portola Pharm Inc | 2,4-diokso-3-chinazolinyloarylowe pochodne sulfonylomocznika |
| WO2005105777A1 (en) * | 2004-05-05 | 2005-11-10 | Pharmacia & Upjohn Company Llc | Substituted thiophene amide compounds for the treatment of inflammation |
| WO2006039212A2 (en) | 2004-09-29 | 2006-04-13 | Portola Pharmaceuticals, Inc. | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
| WO2006085815A1 (en) | 2005-02-11 | 2006-08-17 | Astrazeneca Ab | Thiazole derivatives, their process for their preparation and their use in therapy |
| GB0505539D0 (en) | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
| DK200600313A (da) | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
| RU2008140144A (ru) * | 2006-03-10 | 2010-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента |
| TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
| GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| US8486987B2 (en) | 2007-11-16 | 2013-07-16 | University Of Medicine And Dentistry Of New Jersey | Mechanism-based small-molecule parasite inhibitors |
| US8211928B2 (en) * | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| WO2011108689A1 (ja) | 2010-03-05 | 2011-09-09 | 協和発酵キリン株式会社 | ピラゾロピリミジン誘導体 |
| WO2012067265A1 (en) | 2010-11-18 | 2012-05-24 | Kyoto University | Method for screening drugs for suppressing inflammasome activity |
| TW201311693A (zh) | 2011-09-02 | 2013-03-16 | Kyowa Hakko Kirin Co Ltd | 化學激活激素受體活性調節劑 |
| JP6036193B2 (ja) | 2012-11-09 | 2016-11-30 | 国立大学法人富山大学 | インフラマソーム活性制御剤 |
| PL221813B1 (pl) | 2013-02-22 | 2016-05-31 | Univ Medyczny W Lublinie | Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania |
| TW201501713A (zh) | 2013-03-01 | 2015-01-16 | Kyowa Hakko Kirin Co Ltd | 眼炎症性疾病之預防及／或治療劑 |
| CN104513239B (zh) | 2014-12-10 | 2017-08-22 | 沈阳药科大学 | 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用 |
| WO2016119349A1 (zh) | 2015-01-29 | 2016-08-04 | 中国农业大学 | 一种磺酰脲类、磺酰胺基甲酸酯类化合物的制备方法 |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| US10688077B2 (en) | 2015-02-26 | 2020-06-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
| ES2954596T3 (es) | 2015-12-23 | 2023-11-23 | Univ British Columbia | Profármacos unidos a lípidos |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| TW201910314A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| US12408224B2 (en) | 2018-09-27 | 2025-09-02 | Apple Inc. | Radio link monitoring and failure for new radio-unlicensed operation |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
-
2016
- 2016-02-16 JP JP2017560843A patent/JP6929792B2/ja active Active
- 2016-02-16 HR HRP20200214TT patent/HRP20200214T1/hr unknown
- 2016-02-16 EP EP16751821.6A patent/EP3259253B1/en active Active
- 2016-02-16 CN CN202110867103.8A patent/CN113582889B/zh active Active
- 2016-02-16 KR KR1020247036650A patent/KR102948713B1/ko active Active
- 2016-02-16 MA MA41553A patent/MA41553B1/fr unknown
- 2016-02-16 DK DK16751821.6T patent/DK3259253T3/da active
- 2016-02-16 NZ NZ733948A patent/NZ733948A/en unknown
- 2016-02-16 PE PE2021001430A patent/PE20221627A1/es unknown
- 2016-02-16 IL IL253661A patent/IL253661B2/en unknown
- 2016-02-16 HU HUE19187141A patent/HUE055755T2/hu unknown
- 2016-02-16 IL IL273065A patent/IL273065B2/en unknown
- 2016-02-16 ES ES16751821T patent/ES2777626T3/es active Active
- 2016-02-16 AU AU2016222278A patent/AU2016222278B2/en active Active
- 2016-02-16 RS RS20210952A patent/RS62164B1/sr unknown
- 2016-02-16 LT LTEP19187141.7T patent/LT3578547T/lt unknown
- 2016-02-16 PL PL19187141T patent/PL3578547T3/pl unknown
- 2016-02-16 ME MEP-2020-49A patent/ME03737B/me unknown
- 2016-02-16 PE PE2017001395A patent/PE20180160A1/es unknown
- 2016-02-16 MY MYPI2017001188A patent/MY193765A/en unknown
- 2016-02-16 SG SG10202002599XA patent/SG10202002599XA/en unknown
- 2016-02-16 DK DK19187141.7T patent/DK3578547T3/da active
- 2016-02-16 PT PT191871417T patent/PT3578547T/pt unknown
- 2016-02-16 CA CA3250390A patent/CA3250390A1/en active Pending
- 2016-02-16 EP EP21152421.0A patent/EP3888749A1/en active Pending
- 2016-02-16 ES ES19187141T patent/ES2881228T3/es active Active
- 2016-02-16 MA MA056473A patent/MA56473A/fr unknown
- 2016-02-16 CN CN202110865543.XA patent/CN113563264A/zh active Pending
- 2016-02-16 US US15/551,264 patent/US10538487B2/en active Active
- 2016-02-16 PL PL16751821T patent/PL3259253T3/pl unknown
- 2016-02-16 PT PT167518216T patent/PT3259253T/pt unknown
- 2016-02-16 SG SG11201706664QA patent/SG11201706664QA/en unknown
- 2016-02-16 LT LTEP16751821.6T patent/LT3259253T/lt unknown
- 2016-02-16 SI SI201630635T patent/SI3259253T1/sl unknown
- 2016-02-16 SI SI201631297T patent/SI3578547T1/sl unknown
- 2016-02-16 MD MDE20180009T patent/MD3259253T2/ro unknown
- 2016-02-16 RS RS20200258A patent/RS60048B1/sr unknown
- 2016-02-16 CN CN201680010446.XA patent/CN107428696B/zh active Active
- 2016-02-16 WO PCT/AU2016/050103 patent/WO2016131098A1/en not_active Ceased
- 2016-02-16 EP EP19187141.7A patent/EP3578547B1/en active Active
- 2016-02-16 RU RU2017128287A patent/RU2739356C2/ru active
- 2016-02-16 MA MA47440A patent/MA47440B1/fr unknown
- 2016-02-16 MY MYPI2020001281A patent/MY197094A/en unknown
- 2016-02-16 SM SM20200192T patent/SMT202000192T1/it unknown
- 2016-02-16 KR KR1020177025608A patent/KR102727059B1/ko active Active
- 2016-02-16 MX MX2017010528A patent/MX2017010528A/es unknown
- 2016-02-16 CA CA2975192A patent/CA2975192A1/en active Pending
-
2017
- 2017-08-15 MX MX2023001647A patent/MX2023001647A/es unknown
- 2017-08-16 CL CL2017002097A patent/CL2017002097A1/es unknown
-
2019
- 2019-01-08 CL CL2019000060A patent/CL2019000060A1/es unknown
- 2019-08-07 US US16/535,002 patent/US11130731B2/en active Active
-
2020
- 2020-03-18 CY CY20201100252T patent/CY1122832T1/el unknown
- 2020-05-26 AU AU2020203464A patent/AU2020203464B2/en active Active
-
2021
- 2021-07-29 HR HRP20211225TT patent/HRP20211225T1/hr unknown
- 2021-08-11 JP JP2021131251A patent/JP7566699B2/ja active Active
- 2021-08-18 US US17/405,989 patent/US20220112159A1/en active Granted
- 2021-10-28 AU AU2021258033A patent/AU2021258033A1/en not_active Abandoned
-
2023
- 2023-12-14 US US18/540,743 patent/US20240400502A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211225T1 (hr) | Sulfoniluree i srodni spojevi i njihova uporaba | |
| CN103492370B (zh) | 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法 | |
| JP2023040106A (ja) | 統合的ストレス経路のプロドラッグ調節剤 | |
| JP7324196B2 (ja) | 統合的ストレス経路の調節剤 | |
| TWI777014B (zh) | 可作為蛋白質調節劑之雜環醯胺 | |
| JP2020505381A5 (enExample) | ||
| ES2800026T3 (es) | Tratamiento de enfermedades inmunitarias e inflamatorias | |
| JP2021530536A5 (enExample) | ||
| JP7323539B2 (ja) | オキソアクリジニル酢酸誘導体および使用方法 | |
| JP7847123B2 (ja) | 化合物、組成物及び方法 | |
| CN109890808A (zh) | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 | |
| TW200819127A (en) | Novel receptor antagonists and their methods of use | |
| JP2019525962A (ja) | ケモカイン受容体調節剤及びそれの使用 | |
| EA201001127A1 (ru) | Производные пиридина | |
| EA201001129A1 (ru) | Пиримидины в качестве ингибиторов киназы | |
| JP2023540733A5 (enExample) | ||
| JP2022536160A5 (enExample) | ||
| ES2992410T3 (es) | Inhibidores cetónicos de la lisina gingipaína | |
| JP6334066B2 (ja) | ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン | |
| ES2895965T3 (es) | Moduladores del receptor de GABA(A) y métodos para controlar la hiperreactividad de las vías respiratorias y la inflamación en el asma | |
| JP2022535956A5 (enExample) | ||
| ES3039345T3 (en) | 4,5,6,7-tetrahydro-l-benzothiophene modulators of retinoic acid receptor related (rar) orphan nuclear receptors (rors) | |
| JP2022518526A5 (enExample) | ||
| US10538500B2 (en) | Tricyclic prodrugs | |
| EP4401739A1 (en) | Compounds, compositions and methods |